{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:07:00Z","timestamp":1793200020165,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejmech.2025.117305","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T17:01:43Z","timestamp":1737392503000},"page":"117305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Exploiting synthetic lethality in PDAC with antibody drug conjugates and ATR inhibition"],"prefix":"10.1016","volume":"286","author":[{"given":"Tao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianqiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiakang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-8979","authenticated-orcid":false,"given":"Yifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejmech.2025.117305_bib1","first-page":"1686","article-title":"Pancreatic cancer: an increasing global public health concern","volume":"71","author":"Cabasag","year":"2022","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117305_bib2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117305_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117305_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117305_bib5","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA approval summary: enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117305_bib6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12885-015-1772-1","article-title":"Up-regulation of HER2 by gemcitabine enhances the anti-tumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells","volume":"15","author":"Kan","year":"2015","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117305_bib7","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/ijc.32273","article-title":"An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer","volume":"145","author":"Bourillon","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"13","key":"10.1016\/j.ejmech.2025.117305_bib8","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1158\/1078-0432.CCR-16-2401","article-title":"Synthetic lethality exploitation by an anti-trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1\/2-wild-type triple-negative breast cancer","volume":"23","author":"Cardillo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117305_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109875","article-title":"The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damage","volume":"125","author":"Mei","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"16","key":"10.1016\/j.ejmech.2025.117305_bib10","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-20-4557","article-title":"FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117305_bib11","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-20-3119","article-title":"FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer","volume":"27","author":"Wahby","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117305_bib12","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1158\/1078-0432.CCR-16-2411","article-title":"Pancreatic cancer genomes: implications for clinical management and therapeutic development","volume":"23","author":"Dreyer","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117305_bib13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117305_bib14","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117305_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10637-013-0036-7","article-title":"Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor","volume":"32","author":"King","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2025.117305_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115710","article-title":"The recent developments of camptothecin and its derivatives as potential anti-tumor agents","volume":"260","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117305_bib17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/cr.2017.54","article-title":"Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation","volume":"27","author":"Lian","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2025.117305_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176614","article-title":"Mechanisms and emerging strategies for irinotecan-induced diarrhea","volume":"974","author":"Xu","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117305_bib19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an anti-trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjugate Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117305_bib20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2159-8290.CD-22-1368","article-title":"Antibody-exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer","volume":"13","author":"Weng","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117305_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116497","article-title":"Site-specific construction of triptolide-based antibody-drug conjugates","volume":"51","author":"Wei","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117305_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113355","article-title":"Combretastatin A4-derived payloads for antibody-drug conjugates","volume":"216","author":"Huang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117305_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112080","article-title":"Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates","volume":"190","author":"Huang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117305_bib24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"20","author":"Springfeld","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117305_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117305_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21037\/tgh.2019.04.04","article-title":"Adjuvant treatment for pancreatic cancer","volume":"4","author":"Klaiber","year":"2019","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.ejmech.2025.117305_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.gde.2013.12.001","article-title":"Pancreatic cancer genomics","volume":"24","author":"Chang","year":"2014","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117305_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab021","article-title":"Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity","volume":"3","author":"Gayle","year":"2021","journal-title":"NAR Cancer"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117305_bib29","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","article-title":"A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma","volume":"34","author":"Xing","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117305_bib30","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1021\/acs.jmedchem.9b01684","article-title":"The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor","volume":"63","author":"Goldberg","year":"2020","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117305_bib31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nchembio.1455","article-title":"A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses","volume":"10","author":"Liang","year":"2014","journal-title":"Nat. Chem. Biol."},{"issue":"15","key":"10.1016\/j.ejmech.2025.117305_bib32","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1093\/nar\/gks353","article-title":"RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells","volume":"40","author":"Budke","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117305_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117305_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22708","article-title":"Enriched cancer stem cells, dense stroma, and cold immunity: interrelated events in pancreatic cancer","volume":"35","author":"Mortezaee","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117305_bib35","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.ymthe.2022.04.013","article-title":"A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors","volume":"30","author":"Wu","year":"2022","journal-title":"Mol. Ther."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T15:33:14Z","timestamp":1740411194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":35,"alternative-id":["S0223523425000704"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117305","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting synthetic lethality in PDAC with antibody drug conjugates and ATR inhibition","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117305"}}